Search results

  • Legend Biotech Appoints Lori Macomber as Chief Financial Officer

    SOMERSET, N.J.— (BUSINESS WIRE)—May 9, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the promotion of Lori Macomber, CPA, to Chief Financial Officer (CFO), effective immediately. Ms. Macomber assumes the role from Dr. Ying Huang, who has been both CFO […]

  • Legend Biotech Announces Participation in Upcoming Investor Conferences in May

    SOMERSET, N.J.—May 6, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences: Event: Bank of America Securities 2022 Healthcare ConferencePresentation Date & Time: Wednesday, May 11, 2022 at 5:20pm PT / 8:20pm ETLocation: Las […]

  • Legend Biotech Chairman Frank Zhang awarded 2018 Person of the Year from China Healthcare Summit

    Piscataway, NJ (November 14, 2018): China Healthcare Summit 2018 hosted by BioCentury and BayHelix announced Dr. Frank Zhang, GenScript’s founder, as the winner of its Person of the Year Award. The goal of this award was to recognize an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem of drug and/or medical technology R&D, […]

  • Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

    28-month, median follow-up data from the CARTITUDE-1 study of cilta-cel in patients with relapsed or refractory multiple myeloma presented at the 2022 ASCO Annual meeting Overall response rate remains at 98 percent after more than two years, with median progression-free and overall survival not yet being reached Results from Cohorts A and B of the […]

  • Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

    SOMERSET, N.J.—(BUSINESS WIRE)—June 3, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate LB1908 in a Phase 1 clinical trial in the United […]

  • Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights

    SOMERSET, N.J. — (BUSINESS WIRE) —June 1, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2022 unaudited financial results. “The year began with an exciting start as we received the company’s first-ever U.S. FDA approval for […]

  • Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board

    SOMERSET, N.J.— (BUSINESS WIRE)—August 4, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang “Frank” Zhang as Class II director […]

  • Legend Biotech Corporation Announces Proposed Public Offering (July 25, 2022)

    SOMERSET, NJ – July 25, 2022 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it intends to offer and sell $250 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, in an underwritten public offering. All […]

  • Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T

    SOMERSET, N.J.— (BUSINESS WIRE) —April 21, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the achievement of a $50 million milestone under its collaboration agreement with Janssen Biotech, Inc. (Janssen) for ciltacabtagene autoleucel (cilta-cel), now marketed in the United […]

  • Legend Biotech Announces Appointment of Global Head of Research and Early Development

    SOMERSET, N.J.— (BUSINESS WIRE) —April 1, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Guowei Fang, Ph.D., as Senior Vice President, Global Head of Research and Early Development. Dr. Guowei Fang is an accomplished scientist and […]

close

You are about to leave LegendBiotech.com

You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.